Navigation Links
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Date:3/14/2008

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial of 100 patients that evaluates the safety and efficacy of its lead product, MM-093, in patients suffering from rheumatoid arthritis (RA). MM-093 is a recombinant version of human alpha-fetoprotein (AFP).

The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at 20 centers throughout the United States. The objective of this study is to examine the safety and efficacy of MM-093 in patients with moderate to severe, active RA despite treatment with stable doses of methotrexate. Each patient receives 60mg of MM-093 per week or placebo for 12 weeks and will then be followed for a period of 4 weeks. In addition to evaluating the safety of MM-093, patients will be assessed for changes in the signs and symptoms of their disease using standard clinical outcome measurements for RA, such as ACR20 and DAS28 scores. Patients who complete the study are eligible to participate in an ongoing Open-Label Extension study, which has enrolled over 35 patients to date.

"We are pleased to have completed enrollment and are thankful for the enthusiasm of the investigators who have worked diligently to enroll patients," said Dr. William Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "We believe MM-093 represents a promising and novel approach to the treatment of a broad range of autoimmune diseases. We look forward to completing the study and communicating the results later this year."

In addition to the ongoing studies in RA, MM-093 is currently being tested in a pilot study for patients with certain types of autoimmune uveitis, an inflammatory disorder of the eye.

Merrimack controls a strong intellectual property estate around MM-093 including 15 issued patents and a number of pending applications, both in the U.S. and internationally, which cover composition of matter, production methods and therapeutic uses of the drug.

Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmunity and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Senior Manager, Corporate Communications,

617-441-1043


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
4. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
11. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology:
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 ... ... featuring an inspirational interview of two ostomy patients, standing as living proof that ... people suffer from digestive diseases and issues that spike around the holidays. This ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference ... and Spa in Honolulu, offering local frontline clinicians the opportunity to extend their ... The demand for supplemental training related to pain management has surged dramatically in ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... FL (PRWEB) , ... December 02, 2016 , ... ‘Tis ... are winners of $1,000 each from the National Family Partnership and the Drug Enforcement ... families who decorated their homes and the 10 winning schools who decorated their campuses ...
(Date:11/30/2016)... Beach Gardens, FL (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... provides specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both ...
Breaking Medicine News(10 mins):